CANBridge Life Sciences

46 articles about CANBridge Life Sciences

• 

  AVEO Reclaims Full Global Rights to Antibody Drug from CANbridge

  3/15/2021

  Nearly five years to the day after striking the deal, AVEO Oncology and CANbridge Life Sciences announce the termination of their collaboration and licensing agreement for AVEO’s AV-203.  

• Shanghai Foundation for Rare Disease Appoints CANbridge CEO, James Xue, Deputy Director General

  1/6/2020

  CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced that James Xue, PhD, CANbridge Founder, Chairman and CEO, was named one of six Deputy Director Generals at the Second General Election Meeting of the Shanghai Foundation for Rare Disease, in Shanghai, China on December 21st.

• CANbridge Receives Hong Kong Department of Health Market Approval for NERLYNX®

  11/5/2019

  First CANbridge Oncology Targeted Therapy to be Approved

• CANbridge Pharmaceuticals Appoints Senior Vice President, Rare Disease Commercial Operations

  7/30/2019

  Marcelo Cheresky to the position of Senior Vice President, Rare Disease Commercial Operations, effective as of July 16, 2019.

• 

  Companies Continue to Take Aim at Glioblastoma, a Cancer Highlighted by the Death of Sen. John Mc...

  8/27/2018

  McCain died Saturday after deciding to discontinue treatment for brain cancer. He approached the end of his life in the same manner in which he approached me that day in Raleigh – with the strength of character.

• CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China

  8/14/2018

  CANbridge Life Sciences, a biopharmaceutical company developing Western drug candidates in China and North Asia, announced that the China National Drug Administration (CNDA) has approved the Investigational New Drug (IND) application for a Phase Ib/III clinical study of CAN017 in esophageal squamous cell cancer (ESCC).

• AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China

  8/14/2018

  ND acceptance triggers $2M milestone payment from CANbridge to AVEO.

• Apogenix Strengthens Patent Position for Lead Drug Candidate Asunercept

  8/1/2018

  Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that it was granted two key patents for lead immuno-oncology candidate asunercept in multiple territories.

• CANbridge Life Sciences Appoints Chief Medical Officer

  7/31/2018

  Dr. Orfali replaced Dr. Mark Goldberg, who was acting as interim Chief Medical Officer.

• CANbridge Receives China Food and Drug Administration Approval for CAN002 as Cancer Adjuvant Therapy

  4/26/2018

  CANbridge Life Sciences announced that it received an Import Medical Device Market Approval from the China Food and Drug Administration (CFDA) for CAN002 as a cancer adjuvant therapy, on April 2, 2018.

• CANbridge Receives Approval to Commence CAN008 Phase II/III Trial in Glioblastoma Multiforme (GBM) in China

  4/12/2018

  Multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate efficacy and safety profiles of weekly CAN008 + re-radiation therapy (rRT) in patients with glioblastoma

• 

  European Regulatory Committee Recommends Rejecting Puma Biotechnology’s Breast Cancer Medicine

  2/23/2018

  The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) offered a negative opinion on Puma Biotechnology’s application for neratinib for breast cancer.

• Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX (neratinib) in Greater China

  2/2/2018

  CANbridge Life Sciences announced today that it has licensed the exclusive rights to develop and commercialize NERLYNX (neratinib) in China, Taiwan, Hong Kong and Macao (collectively, greater China) from Puma Biotechnology.

• CANbridge Life Sciences Appoints VP of Regulatory Affairs and Quality

  1/16/2018

  The position is a new one, as CANbridge ramps up its leadership in anticipation of upcoming regulatory filings expected for several of its programs

• CANbridge Life Sciences Submits Investigational NDA for CAN017 Trial in Esophageal Squamous Cell Cancer (ESCC) in China

  12/21/2017

  CANBridge Life Sciences announced that it has submitted an IND application to the CFDA for a Phase Ib/III clinical study of CAN017 in ESCC.

• AVEO Oncology Announces Receipt Of Payments From EUSA Pharma And CANBridge Life Sciences

  9/13/2017

• CANBridge Life Sciences Appoints Chief Business Officer Will Head First U.S. Office

  9/12/2017

• CANBridge Life Sciences Raises $25 Million In Series B Round Led By Lapam Capital

  5/23/2017

• CANBridge Life Sciences And AmoyDx Enter Into Strategic Partnership For CAN008 Companion Diagnostic Development

  5/16/2017

• AVEO Oncology Announces Milestone Payment From CANBridge Life Sciences For AV-203

  4/3/2017